sprout health tirzepatide GLP-1 Assessment How Tirzepatide Supports Brain Health

Tirzepatide led to a significantly greater reduction in glucose total AUC (41%) compared to semaglutide (34%) and placebo (1% increase)

In comparison, Mazdutide is still confined to clinical trials, meaning its not yet available to the public

GLP1 and GIP hormones play a critical role in sending satiety messages to the brain

The SURMOUNT-4 trial showed that stopping treatment led to weight regain, while continued use maintained and even increased weight loss (25.3% total at 88 weeks)

Tirzepatide slows gastric emptying and promotes satiety, which can lead to decreased food and fluid consumption

This temporary shedding is called telogen effluvium, and hair usually regrows once weight loss slows and nutrition improves